Skip to content

Clinical efficacy observation of sodium ferulate in the treatment on mild cognitive impairment

Clinical efficacy observation of sodium ferulate in the treatment on mild cognitive impairment

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070778
Enrollment
Unknown
Registered
2023-04-23
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

Experimental group:Give the subjects oral administration of sodium ferulate tablets, one tablet per time, three times a day, for 100 consecutive days
Regular follow-up and clinical symptom observation and evaluation.
Control group:Give the subjects oral administration of placebo tablets, one tablet per time, three times a day, for 100 consecutive days

Sponsors

the 71st Group Army Hospital of CPLA Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: ?complained of memory loss and confirmed by others; ?Clinical evaluation confirmed cognitive impairment, impairment of logical memory such as delayed story recall (DSR) score at least 1.5 SD lower than the average of age - or education-matched population, other cognitive areas remained relatively intact and did not meet the criteria for dementia; ?The score of mini-mental state examination ( MMSE ) was between 24 and 30; ?Clinical Dementia Rating Scale ( CDR ) = 0.5, amnestic CDR scale memory item score at least 0.5 ; ?Activities of daily living intact or very slight impairment, such as instrumental activities of daily living (IADL) score of 16 or greater; ?No dementia.

Exclusion criteria

Exclusion criteria: ?Those who do nry of severe cerebrovascular disease; ?Those with a history of deot meet the above inclusion criteria; ?patients with a histopression within 2 years; ?patients with severe allergic diseases such as allergic shock ; ?patients with alcohol, mental drug abuse or dependence within 2 years ; ?Patients who had taken anticholinergic drugs, antidepressants, ginkgo biloba preparations before this study.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MoCA);Alzheimer’s Disease Assessment Scale-Cognitive Section (ADAS-cog);Delayed Story Recall (DSR);Mini-mental State Examination (MMSE);Activity of Daily Life ( ADL);Clinical Dementia Rating (CDR);clinical efficacy;

Countries

China

Contacts

Public ContactHong Qian

the 71st Group Army Hospital of CPLA Army

hongqian177@126.com+86 13626166186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026